c/trialwatch · created 4 Nov 2023
STEP, SURMOUNT, SURPASS, SELECT, FLOW, TRIUMPH — read the appendix.
Genuinely asking, not being difficult. Everyone in c/compounding repeats that hazard ratio is important. I believe it, but I have never seen anyone show why, and when I…
Trying to settle this properly because the thread from last year went in circles. The claim: FLOW matters. The counter-claim: it is measurement error. Both sides have…
Quick one. Canada here. endpoint works very differently where I live than in the threads that dominate the front page, and I keep seeing people confidently given advice…
Right, the TRIUMPH question again, but with numbers this time. I have 8 data points over 28 weeks. The pattern is consistent enough that I do not think it is chance,…
Reference standards, analytical reagents and system-suitability material. If you are running your own method, start with a known.
Reference standardsFLOW (Perkovic et al., N Engl J Med , 2024) reported a hazard ratio of 0.76 for the composite kidney endpoint in people with type 2 diabetes and chronic kidney disease.…
Clinical trial reading group. New readouts, protocol amendments, endpoint definitions, dropout handling, and the difference between a press release and a publication. Absolute risk reduction and number-needed-to-treat are house dialect here.
Independent testing plus vendor-level trend data. Community-funded, unaffiliated.
peptidemeter.comSeveral compounds discussed on GLP Research Hub are sold for research use only and are not approved for human use anywhere. Nothing here is medical advice and none of it is written by your clinician. If a post reads like an instruction, treat it as a description of what one stranger did.
Reference